PMID: 3759253Jan 1, 1986Paper

Treatment of respiratory tract infections with imipenem/cilastatin in critical patients with respiratory insufficiency

Infection
K UnertlF P Lenhart

Abstract

In an open prospective study the efficacy and tolerance of imipenem/cilastatin was investigated in 24 critically ill patients on mechanical ventilation with nosocomial respiratory tract infection. Nine patients had previously received antibiotic therapy, eight of them with various other beta-lactam antibiotics which had failed. Imipenem was given in a dose of 1-3 g/24 h over 5-37 (mean 11) days. Seven patients were additionally treated with aminoglycosides, one patient with erythromycin. Pseudomonas aeruginosa (n = 14), Staphylococcus aureus (n = 4), Haemophilus influenzae (n = 4) and Escherichia coli (n = 3) were the potential pathogens most frequently isolated from tracheo-bronchial secretions. All of the isolates were susceptible to imipenem. 91% of the infections without and 77% with involvement of P. aeruginosa were successfully treated. Two patients who had not responded to previous treatment succumbed to the consequences of progressive respiratory distress syndrome. All of the gram-positive and 85% of the gram-negative pathogens (Pseudomonas not included) were eliminated in the course of therapy. By contrast, 64% of the isolates of P. aeruginosa persisted; half of these became imipenem-resistant. Nine patients showed adv...Continue Reading

References

Sep 1, 1975·Postgraduate Medicine·L R Crane, A M Lerner
Jun 7, 1985·The American Journal of Medicine·R A SalataR J Duma
Jun 7, 1985·The American Journal of Medicine·R N Jones
Jul 1, 1985·Reviews of Infectious Diseases·P M Shah
Jul 1, 1985·Reviews of Infectious Diseases·C WangK R Brown
Jul 15, 1985·The American Journal of Medicine·A KarnadS L Berk
Jan 1, 1966·Medicine·J R Tillotson, A M Lerner
Dec 1, 1983·The Journal of Antimicrobial Chemotherapy·J D Baumgartner, M P Glauser
Jan 1, 1984·Reviews of Infectious Diseases·G L DrusanoW L Hewitt
Oct 1, 1984·European Journal of Clinical Microbiology·I Braveny
Mar 1, 1983·Reviews of Infectious Diseases·G P BodeyL Jadeja
Dec 1, 1983·The Journal of Antimicrobial Chemotherapy·H C Neu
Nov 1, 1984·Antimicrobial Agents and Chemotherapy·D J WinstonR W Busuttil
Jan 1, 1981·The Journal of International Medical Research·J WelterV Freitag

❮ Previous
Next ❯

Citations

Jan 1, 1990·Scandinavian Journal of Infectious Diseases. Supplementum
Jan 1, 1992·Intensive Care Medicine·K E UnertlK Peter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

The Journal of Antimicrobial Chemotherapy
F Philip-JoetA Arnaud
Diagnostic Microbiology and Infectious Disease
M J RobbinsR N Grüneberg
Genitourinary Medicine
E MonteiroR C Spencer
© 2021 Meta ULC. All rights reserved